Frazier Life Sciences Management L.P. Makes New $3.79 Million Investment in Xilio Therapeutics, Inc. $XLO

Frazier Life Sciences Management L.P. acquired a new position in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 5,915,091 shares of the company’s stock, valued at approximately $3,787,000. Frazier Life Sciences Management L.P. owned 8.76% of Xilio Therapeutics at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. State Street Corp increased its position in Xilio Therapeutics by 13.7% during the 4th quarter. State Street Corp now owns 186,390 shares of the company’s stock worth $119,000 after buying an additional 22,500 shares during the period. Jane Street Group LLC bought a new position in Xilio Therapeutics during the 4th quarter worth $27,000. Squarepoint Ops LLC increased its position in Xilio Therapeutics by 39.6% during the 3rd quarter. Squarepoint Ops LLC now owns 328,794 shares of the company’s stock worth $277,000 after buying an additional 93,338 shares during the period. Renaissance Technologies LLC increased its position in Xilio Therapeutics by 68.3% during the 4th quarter. Renaissance Technologies LLC now owns 344,416 shares of the company’s stock worth $220,000 after buying an additional 139,716 shares during the period. Finally, Velan Capital Investment Management LP bought a new position in Xilio Therapeutics during the 4th quarter worth $109,000. Institutional investors own 54.29% of the company’s stock.

Wall Street Analysts Forecast Growth

XLO has been the topic of several recent research reports. Wall Street Zen cut Xilio Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings cut Xilio Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, May 26th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to MarketBeat, Xilio Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $28.00.

Xilio Therapeutics Stock Performance

Shares of NASDAQ XLO opened at $8.31 on Friday. The stock’s fifty day moving average is $8.23 and its 200 day moving average is $8.55. The stock has a market capitalization of $54.68 million, a P/E ratio of -2.34 and a beta of -0.12. Xilio Therapeutics, Inc. has a 52 week low of $6.47 and a 52 week high of $12.74.

Xilio Therapeutics (NASDAQ:XLO) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.08. The business had revenue of $12.65 million for the quarter, compared to analyst estimates of $8.52 million. Xilio Therapeutics had a negative return on equity of 151.42% and a negative net margin of 58.52%.

Xilio Therapeutics Company Profile

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.